Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients. / Sondergaard, Lars.

I: J A C C: Cardiovascular Interventions, Bind 9, Nr. 21, 14.11.2016, s. 2183-2185.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Sondergaard, L 2016, 'Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients', J A C C: Cardiovascular Interventions, bind 9, nr. 21, s. 2183-2185. https://doi.org/10.1016/j.jcin.2016.08.015

APA

Sondergaard, L. (2016). Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients. J A C C: Cardiovascular Interventions, 9(21), 2183-2185. https://doi.org/10.1016/j.jcin.2016.08.015

Vancouver

Sondergaard L. Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients. J A C C: Cardiovascular Interventions. 2016 nov. 14;9(21):2183-2185. https://doi.org/10.1016/j.jcin.2016.08.015

Author

Sondergaard, Lars. / Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients. I: J A C C: Cardiovascular Interventions. 2016 ; Bind 9, Nr. 21. s. 2183-2185.

Bibtex

@article{f09abacfec64412daf18900c47f50e03,
title = "Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients",
abstract = "During the last decade transcatheter aortic valve replacement (TAVR) has been established as a treatment for patients with severe aortic stenosis, who are at particularly high surgical risk. As compared with surgical aortic valve replacement (SAVR), TAVR has been associated with lower early risk of mortality, atrial fibrillation, acute kidney injury, and bleeding. Furthermore, device and periprocedural improvements have addressed most of the initial limitations for TAVR, including the Achilles{\textquoteright} heel, paravalvular leakage. Supported by this as well as preliminary data among lower-risk patients, TAVR is currently being evaluated in prospective randomized trials against SAVR in younger low-risk patients. Although durability of the TAVR device may be of concern in younger patients given their longer life expectancy, intermediate-term controlled data does not reveal any difference between TAVR and SAVR devices.",
keywords = "aortic stenosis, risk, SAVR, TAVR",
author = "Lars Sondergaard",
year = "2016",
month = nov,
day = "14",
doi = "10.1016/j.jcin.2016.08.015",
language = "English",
volume = "9",
pages = "2183--2185",
journal = "J A C C: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier",
number = "21",

}

RIS

TY - JOUR

T1 - Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients

AU - Sondergaard, Lars

PY - 2016/11/14

Y1 - 2016/11/14

N2 - During the last decade transcatheter aortic valve replacement (TAVR) has been established as a treatment for patients with severe aortic stenosis, who are at particularly high surgical risk. As compared with surgical aortic valve replacement (SAVR), TAVR has been associated with lower early risk of mortality, atrial fibrillation, acute kidney injury, and bleeding. Furthermore, device and periprocedural improvements have addressed most of the initial limitations for TAVR, including the Achilles’ heel, paravalvular leakage. Supported by this as well as preliminary data among lower-risk patients, TAVR is currently being evaluated in prospective randomized trials against SAVR in younger low-risk patients. Although durability of the TAVR device may be of concern in younger patients given their longer life expectancy, intermediate-term controlled data does not reveal any difference between TAVR and SAVR devices.

AB - During the last decade transcatheter aortic valve replacement (TAVR) has been established as a treatment for patients with severe aortic stenosis, who are at particularly high surgical risk. As compared with surgical aortic valve replacement (SAVR), TAVR has been associated with lower early risk of mortality, atrial fibrillation, acute kidney injury, and bleeding. Furthermore, device and periprocedural improvements have addressed most of the initial limitations for TAVR, including the Achilles’ heel, paravalvular leakage. Supported by this as well as preliminary data among lower-risk patients, TAVR is currently being evaluated in prospective randomized trials against SAVR in younger low-risk patients. Although durability of the TAVR device may be of concern in younger patients given their longer life expectancy, intermediate-term controlled data does not reveal any difference between TAVR and SAVR devices.

KW - aortic stenosis

KW - risk

KW - SAVR

KW - TAVR

U2 - 10.1016/j.jcin.2016.08.015

DO - 10.1016/j.jcin.2016.08.015

M3 - Review

C2 - 27744040

AN - SCOPUS:84994389301

VL - 9

SP - 2183

EP - 2185

JO - J A C C: Cardiovascular Interventions

JF - J A C C: Cardiovascular Interventions

SN - 1936-8798

IS - 21

ER -

ID: 179210667